Interleukin 6 is required for the development of collagen-induced arthritis

Journal of Experimental Medicine

Volumn 187, Issue 4, 1998, Pages 461-468

  Alonzi, Tonino ^a   Fattori, Elena ^a   Lazzaro, Domenico ^a   Costa, Patrizia ^a   Probert, Lesley ^b   Kollias, George ^b   De Benedetti, Fabrizio ^c   Poli, Valeria ^a   Ciliberto, Gennaro ^a  

^a IRBM   (Italy)

^b HELLENIC PASTEUR INSTITUTE   (Greece)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DINITROPHENOL; COLLAGEN TYPE 2; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTHRITIS; ARTICLE; CONTROLLED STUDY; MALE; MOUSE; MUTATION; NONHUMAN; POLYARTHRITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS; COLLAGEN; DRUG INTERACTIONS; INTERLEUKIN-6; MALE; MICE; MICE, INBRED DBA; MICE, KNOCKOUT; MICE, TRANSGENIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032536542     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.187.4.461     Document Type: Article

References (52)

1. Feldmann, M., F.M. Brennan, and R.N. Maini. 1996. Rheumatoid arthritis. Cell. 85:307-310.
2. Feldmann, M., F.M. Brennan, and R.N. Maini. 1996. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14: 397-440.
3. Guerne, A.P., B.L. Zuraw, J.H. Vaughan, D.A. Carson, and M. Lotz. 1989. Synovium as a source of interleukin-6 in vivo. Contribution to local and systemic manifestations of arthritis. J. Clin. Invest. 83:585-592.
4. Houssiau, F.A., J.P. Devogelaer, J. Van Damme, C.N. de Deuxchaines, and J. Van Snick. 1988. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 31:784-788.
5. De Benedetti, F., M. Massa, P. Robbioni, A. Ravelli, G.R. Burgio, and A. Martini. 1991. Correlation of serum interleukin 6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 34: 1158-1163.
6. De Benedetti, F., P. Robbioni, M. Massa, S. Viola, S. Albani, and A. Martini. 1992. Serum interleukin 6 and joint involvement in polyarticular and pauciarticular in systemic juvenile chronic arthritis. Clin. Exp. Rheumatol. 10:493-498.
7. Kotake, S., K. Sato, N. Takahashi, N. Udagawa, I. Nakamura, A. Yamaguchi, T. Kishimoto, T. Suda, and T. Kashiwazaki. 1996. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J. Bone Miner. Res. 11:88-95.
8. De Benedetti, F., M. Massa, P. Pignatti, S. Albani, D. Novick, and A. Martini. 1994. Serum soluble IL-6 receptor and IL-6/soluble IL-6 receptor complex in juvenile rheumatoid arthritis. J. Clin. Invest. 93:2114-2119.
9. Kishimoto, T., S. Akira, and T. Taga. 1992. Interleukin-6 and its receptor: a paradigm for cytokines. Science. 258:593-597.
10. Van Snick, J. 1990. Interleukin-6 an overview. Annu. Rev. Immunol. 8:253-278.
11. Romano, M., M. Sironi, C. Toniatti, N. Polentarutti, P. Fruscella, P. Ghezzi, R. Faggioni, W. Luini, V. van Hinsbergh, S. Sozzani, et al. 1997. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity. 6:315-325.
12. Mihara, M., Y. Moriya, T. Kishimoto, and Y. Ohsugi. 1995. Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br. J. Rheumatol. 34:321-325.
13. Tamura, T., N. Udagawa, N. Takahashi, C. Miyaura, S. Tanaka, Y. Yamada, Y. Koishihara, Y. Ohsugi, K. Kumaki, and T. Taga. 1993. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc. Natl. Acad. Sci. USA. 90:11924-11928.
14. Chai, Z., S. Gatti, C. Toniatti, V. Poli, and T. Bartfai. 1996. IL-6 gene expression in the CNS is necessary for fever response to LPS or IL-1β: a study on IL-6-deficient mice. J. Exp. Med. 183:311-316.
15. Poli, V., and G. Ciliberto. 1994. Transcriptional regulation of acute phase genes by IL-6 and related cytokines. In Liver Gene Expression. F. Tronche and M. Yaniv, editors. R.G. Landes Company Biomedical Publishers, Austin. 131-151.
16. Kopf, M., G. Le Gros, A.J. Coyle, M. Kosco-Vilbois, and F. Brombacher. 1995. Immune response of IL-4, IL-5, IL-6 deficient mice. Immunol. Rev. 148:45-70.
17. Poli, V., R. Balena, E. Fattori, A. Markatos, M. Yamamoto, H. Tanaka, G. Ciliberto, G.A. Rodan, and F. Costantini. 1994. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO (Eur. Mol. Biol. Organ.) J. 13:1189-1196.
18. Lattanzio, G., C. Libert, M. Aquilina, M. Cappelletti, G. Ciliberto, P. Musiani, and V. Poli. 1997. Defective development of pristane oil-induced plasmacytomas in IL-6-deficient Balb/c mice. Am. J. Pathol. 151:689-696.
19. Keffer, J., L. Probert, H. Cazlaris, S. Georgopoulos, E. Kaslaris, D. Kioussis, and G. Kollias. 1991. Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO (Eur. Mol. Biol. Organ.) J. 10: 4025-4031.
20. Vink, A., P. Coulie, G. Warnier, J.C. Renauld, M. Stevens, D. Donckers, and J. Van Snick. 1990. Mouse plasmacytoma growth in vivo: enhancement by interleukin-6 (IL-6) and inhibition by antibodies direct against IL-6 or its receptor. J. Exp. Med. 172:997-1000.
21. Heremans, H., C. Dillen, W. Put, J. Van-Damme, and A. Billiau. 1992. Protective effect of anti-interleukin (IL)-6 antibody against endotoxin, associated with paradoxally increased IL-6 levels. Eur. J. Immunol. 22:2395-2401.
22. Holmdahl, R., M. Andersson, T.J. Goldschidt, K. Gustafsson, L. Jansson, and J.A. Mo. 1990. Type II collagen autoimmunity in animals and provocations leading to arthritis. Immunol. Rev. 118:193-232.
23. Libert, C., A. Vink, P. Coulie, P. Brouckarter, B. Everaerdt, J. Van Snick, and W. Fiers. 1992. Limited involvement of interleukin-6 in the pathogenesis of lethal septic shock as revealed by the effect of monoclonal antibodies against interleukin-6 or its receptors in various murine models. Eur. J. Immunol. 22:2625-2630.
24. Giraudo, E., M. Arese, C. Toniatti, M. Strasly, L. Primo, A. Mantovani, G. Ciliberto, and F. Bussolino. 1996. IL-6 is an in vitro and in vivo autocrine growth factor for middle T antigen-transformed endothelial cells. J. Immunol. 157:2618-2623.
25. De Benedetti, F., T. Alonzi, A. Moretta, D. Lazzaro, P. Costa, V. Poli, A. Martini, G. Ciliberto, and E. Fattori. 1997. IL-6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I: a model for stunted growth in children with chronic inflammation. J. Clin. Invest. 99:1-8.
26. Watson, W.C., and A.S. Townes. 1985. Genetic susceptibility to murine collagen II autoimmune arthritis. Proposed relationship to the IgG2 autoantibody subclass response, complement C5, major histocompatibility complex (MHC) and non-MHC loci. J. Exp. Med. 162:1878-1891.
27. Boissier, M.C., A. Carlioz, and C. Fournier. 1988. Experimental autoimmune arthritis in mice. II. Early events in the elicitation of the autoimmune phenomenon induced by homologous type II collagen. Clin. Immunol. Immunopathol. 48: 225-237.
28. 2 cell differentiation factor BSF-2/hepatocyte-stimulating factor gene in human fibroblasts by other cytokines. J. Immunol. 140:974-977.
29. Aderka, D., J. Le, and J. Vilcek. 1989. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J. Immunol. 143:3517-3523.
30. Fattori, E., M. Cappelletti, P. Costa, C. Sellitto, L. Cantoni, M. Carelli, R. Faggjoni, G. Fantuzzi, F. Ghezzi, and V. Poli. 1994. Defective inflammatory response in IL-6-deficient mice. J. Exp. Med. 180:1243-1250.
31. Lu, Z.Y., H. Brailly, J. Wijdenes, R. Bataille, J.F. Rossi, and B. Klein. 1995. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood. 86:3123-3131.
32. Suzuki, H., K. Yasukawa, T. Saito, M. Narazaki, A. Hasegawa, T. Taga, and T. Kishimoto. 1993. Serum soluble interleukin-6 receptor in MRL/lpr mice is elevated with age and mediates the interleukin-6 signal. Eur. J. Immunol. 23:1078-1082.
33. Sany, J. 1994. Intravenous immunoglobulin therapy for rheumatic diseases. Curr. Opin. Rheumatol. 6:305-310.
34. Mon, L., S. Iselin, G. De Libero, and W. Lesslauer. 1996. Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J. Immunol. 157:3178-3182.
35. McIntyre, K.M., D.J. Shuster, K.M. Gillooly, R.R. Warrier, S.E. Connaughton, L.B. Hall, L.H. Arp, M.K. Gately, and J. Magram. 1996. Reduced incidence and seventy of collagen-induced arthritis in interleukin-12-deficient mice. Eur. J. Immunol. 26:2933-2938.
36. Bullard, D.C., L.A. Hurley, I. Lorenzo, L.M. Sly, A.L. Beaudet, and N.D. Staite. 1996. Reduced susceptibility to collagen-induced arthritis in mice deficient in intracellular adhesion molecule-1. J. Immunol. 157:3153-3158.
37. Tada, Y., A. Ho, T. Matsuyama, and T.W. Mak. 1997. Reduced incidence and severity of antigen-induced autoimmune diseases in mice lacking interferon regulatory factor-1. J. Exp. Med. 185:231-238.
38. Griffiths, R.J., M.A. Smith, M.L. Roach, J.L. Stock, E.J. Stam, A.J. Milici, D.N. Scampoli, J.D. Eskra, R.S. Byrum, B.H. Koller, and J.D. McNeish. 1997. Collagen-induced arthritis is reduced in 5-lipoxygenase-activating protein-deficient mice. J. Exp. Med. 185:1123-1129.
39. Tada, T., A. Ho, D.R. Koh, and T.W. Mak. 1996. Collagen-induced arthritis in CD4- or CD8-deficient mice. J. Immunol. 156:4520-4526.
40. Remmers, E.F., R.E. Longman, Y. Du, A. O'Hare, G.W. Cannon, M.M. Griffiths, and R.L. Wilder. 1996. A genome scan localizes five non-MHC loci controlling collagen-induced arthritis in rats. Nat. Genet. 14:82-85.
41. Jansson, L., and R. Holmdahl. 1993. Genes on the X chromosome affect development of collagen-induced arthritis in mice. Clin. Exp. Immunol. 94:459-465.
42. Okada, M., M. Kitahara, S. Kishimoto, T. Matsuda, T. Hirano, and T. Kishimoto. 1988. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J. Immunol. 141:1543-1549.
43. Chioccia, G., M.C. Boissier, B. Manoury, and C. Fournier. 1993. T cell regulation of collagen-induced arthritis in mice. II. Immunomodulation of arthritis by cytototoxic T cell hybridomas specific for type II collagen. Eur. J. Immunol. 23: 327-332.
44. Douni, E., K. Akassoglou, L. Alexopoulou, S. Georgopoulos, S. Haralambous, S. Hill, G. Kassiotis, D. Kontoyiannis, M. Pasparakis, D. Plows, et al. 1996. Transgenic and knockout analyses of the role of TNF in immune regulation and disease pathogenesis. J. Inflamm. 47:27-38.
45. Probert, L., D. Plows, G. Kontogeorgos, and G. Kollias. The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice. Eur. J. Immunol. 25:1794-1797.
46. Joosten, L.A.B., M. Helsen, F.A. van de Loo, and W.B. van den Berg. 1996. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. Arthritis Rheum. 39:797-809.
47. Lewthwaite, J., S.M. Blake, T.E. Hardingham, P.J. Warden, and B. Henderson. The effect of recombinant human interleukin 1 receptor antagonist on the induction phase of antigen induced arthritis in the rabbit. J. Rheumatol. 21:467-472.
48. Wooley, P.H., J.D. Whalen, D.L. Chapman, A.E. Berger, K.A. Richard, D.G. Asparr, and N.D. Staite. 1993. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum. 36:1305-1314.
49. Elliott, M.J., R.N. Maini, M. Feldmann, J.R. Kalden, C. Antom, J.S. Smolen, B. Leeb, F.C. Breedveld, J.D. Macfarlane, H. Bijl, and J.N. Woody. 1994. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet. 344:1105-1110.
50. Elliott, M.J., P. Woo, P. Charles, A. Long-Fox, J.N. Woody, and R.N. Maini. 1997. Suppression of fever and acute phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-α (cA2). Br. J. Rheumatol. 36:589-593.
51. Wendling, A., E. Racadot, and J. Wijdenes. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J. Rheumatol. 20:259-262.
52. Ciliberto, G., and R. Cortese. 1997. Interleukin-6-blocking agents. Drugs News & Perspectives. 10:394-400.